Research & Development
AstraZeneca unveils BYDUREON BCise Injectable medicine in the US for Type-2 Diabetes
11 January 2018 -

Biopharmaceutical company AstraZeneca disclosed on Wednesday the availability of BYDUREON BCise (exenatide extended-release) injectable suspension 2mg in pharmacies across the US for the treatment of patients with Type-2 Diabetes.

This US launch follows BYDUREON BCise's recent approval by the US Food and Drug Administration for adults with type-2 diabetes whose blood sugar remains uncontrolled on one or more oral antidiabetic medicines in addition to diet and exercise, to improve glycemic control.

According to the company, the BYDUREON BCise is a new formulation of BYDUREON (exenatide extended-release) injectable suspension 2mg in an improved once-weekly, single-dose autoinjector device. It is designed for patient ease and convenience in a pre-filled device with a pre-attached hidden needle. The new formulation is proven to reduce blood sugar levels and is administered in three simple steps – mix, unlock, inject.

Across two clinical trials, average HbA1c reductions of up to 1.4% and average weight loss of up to 3.1 pounds were achieved when used as monotherapy or as an add-on to metformin, a sulfonylurea, a thiazolidinedione, or any combination of two of these oral antidiabetic medicines at 28 weeks, added the company.

In conjunction, the eligible commercially insured patients may pay as low as $0 for BYDUREON BCise every month, concluded the company